Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenza Conteduca

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
The Journal of Clinical Investigation|July 2, 2019
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerAdeline Berger, Nicholas J Brady, Rohan Bareja, et al.
Nature Communications|June 8, 2021
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancerNicholas J Brady, Alyssa M Bagadion, Richa Singh, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
European Urology Open Science|October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Journal of Clinical Medicine|June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted TherapyVincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Future Oncology (London, England)|October 6, 2015
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patientsVincenza Conteduca, Orazio Caffo, Lucia Fratino, et al.
The Journal of Clinical Investigation|March 10, 2020
Genome-wide plasma DNA methylation features of metastatic prostate cancerAnjui Wu, Paolo Cremaschi, Daniel Wetterskog, et al.
European Urology Open Science|February 22, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 StudyChiara Casadei, Emanuela Scarpi, Vincenza Conteduca, et al.
Therapeutic Advances in Urology|April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patientsSebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
The Oncologist|June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective TrialUmberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
The Journal of Clinical Investigation|July 2, 2019
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerAdeline Berger, Nicholas J Brady, Rohan Bareja, et al.
Nature Communications|June 8, 2021
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancerNicholas J Brady, Alyssa M Bagadion, Richa Singh, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
European Urology Open Science|October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Journal of Clinical Medicine|June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted TherapyVincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Future Oncology (London, England)|October 6, 2015
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patientsVincenza Conteduca, Orazio Caffo, Lucia Fratino, et al.
The Journal of Clinical Investigation|March 10, 2020
Genome-wide plasma DNA methylation features of metastatic prostate cancerAnjui Wu, Paolo Cremaschi, Daniel Wetterskog, et al.
European Urology Open Science|February 22, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 StudyChiara Casadei, Emanuela Scarpi, Vincenza Conteduca, et al.
Therapeutic Advances in Urology|April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patientsSebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
The Oncologist|June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective TrialUmberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.
Pageof 16